Bristol-Myers Squibb enters into agreement to expand access to Reyataz.
M2 PHARMA-June 29, 2011-Bristol-Myers Squibb enters into agreement to expand access to Reyataz(C)2011 M2 COMMUNICATIONS
29 June 2011 - US-based biopharmaceutical company Bristol-Myers Squibb Company (NYSE: BMY) yesterday announced a new agreement to expand access to Reyataz (atazanavir sulfate).
The immunity-from-suit agreement signed with India-based Matrix Laboratories Limited enables the generic company to manufacture and sell atazanavir, as well as stavudine and didanosine, in sub-Saharan Africa and India.
Under the terms of the agreement, Matrix Laboratories will secure World Health Organization (WHO) prequalification for all products covered by the agreement, including pediatric formulations of didanosine and, in the future, atazanavir powder formulation for pediatric use when Bristol-Myers Squibb's product is available. WHO prequalification enables procurement organizations to purchase medicines using funding from United Nations agencies and the Global Fund to Fight AIDS, Tuberculosis and Malaria.
The immunity-from-suit agreement with Matrix Laboratories is the fifteenth agreement that Bristol-Myers Squibb has signed for its HIV medicines, and the fourth for atazanavir. A key component of the agreement is the inclusion of pediatric formulations of the medicines to support the treatment needs of children with HIV.
((Comments on this story may be sent to firstname.lastname@example.org))